Neuralace

Menu
Menu
Menu
Menu
Menu

Press & Media

PRESS & MEDIA

Track Our Latest News &
Breakthroughs in Neuromodulation

Track Our Latest News & Breakthroughs in Neuromodulation

Keep up with news, press, and media buzz about Axon Therapy® mPNS.
  • PR NEWSWIRE

Neuralace Medical Announces FDA Clearance of Axon Therapy for Chronic Painful Diabetic Neuropathy

Non-Invasive Magnetic Peripheral Nerve Stimulation (mPNS) Treatment Offers

Non-Invasive Magnetic Peripheral Nerve Stimulation (mPNS) Treatment Offers New Hope for PDN Patients SAN DIEGO, Jan. 11, 2024 /PRNewswire/ — Neuralace Medical, Inc., an innovator in pain management technology, today proudly announces the FDA clearance of its groundbreaking product,

Read More
  • PR NEWSWIRE

Neuralace Medical is Set to Showcase its Non-invasive Axon Therapy Using the Company’s Proprietary Magnetic Peripheral Nerve Stimulation Technology (mPNS), at the North American Neuromodulation Society Conference Highlighted by Clinical Presentations in the Areas of Painful Diabetic Neuropathy and Axon Therapy Extended Use Clinical Data

Dr. Lora Brown will present results of the
Dr. Lora Brown will present results of the Axon Therapy Painful Diabetic Neuropathy (AT-PDN) study demonstrating the clinical impact of Axon Therapy (mPNS) on patients
Read More
  • PR NEWSWIRE

Neuralace Medical Completes Enrollment of Painful Diabetic Neuropathy Label Expansion Study (AT-PDN) Paving the Way for FDA Clearance and a Breakthrough, Non-invasive Treatment for Diabetes related Neuropathic Pain

This milestone marks the potential for significant expansion
This milestone marks the potential for significant expansion of the clinical benefits of neuromodulation to the millions of patients suffering from PDN who may not be candidates for implantable solutions but can benefit from non-invasive neuromodulation
Read More
  • PR NEWSWIRE

Neuralace Medical Announces Clinical Milestones Including Presentation of the Safety and Efficacy of Axon Therapy (SEAT) Study at the American Society of Pain and Neuroscience Conference (ASPN), While Completing Enrollment in the Axon Therapy Painful Diabetic Neuropathy Study (AT-PDN) and Launching a Pilot Study Focused on the Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN)

Neuralace Medical will continue to leverage clinical milestone
Neuralace Medical will continue to leverage clinical milestone progress to support its current seed fundraising efforts highlighted by a recent first close of $3.1M targeting a total raise of $5-$7M
Read More
  • PR NEWSWIRE

Dr. Peter Staats, Chief Medical Officer at National Spine and Pain, Joins the Neuralace Medical Advisory Board as the Company Continues its Successful Seed Round Fundraising, Building Off the First Close of $3.1M While Targeting a Total Capital Raise of $5M-$7M

In addition, the Charlie Norwood VAMC in Augusta,
In addition, the Charlie Norwood VAMC in Augusta, GA Recognizes its Pain Clinic for Spearheading First Use of the Axon Therapy Within the VA Health System
Read More
  • PR NEWSWIRE

Neuralace Medical Announces First Patients Enrolled in the AT-PDN Study Evaluating Axon Therapy® for the Treatment of Painful Diabetic Neuropathy

Neuralace Medical intends to utilize the output of
Neuralace Medical intends to utilize the output of the AT-PDN multicenter study to support the FDA 510(k) application for Axon Therapy label expansion to include Treatment for Painful Diabetic Neuropathy
Read More
  • PR NEWSWIRE

Neuralace Medical Announces Contract Award Totaling $1.4M Over Five Years With The Department of Veterans Affairs, Augusta, Georgia VA for Treatment of Chronic Neuropathic Pain Using Axon Therapy®

The Augusta VA Pain Medicine Service will be
The Augusta VA Pain Medicine Service will be offering Axon Therapy to Veterans using Neuralace's proprietary magnetic peripheral nerve stimulation (mPNS™) technology. Axon Therapy will enable the pain medicine service to combat pain using a non-invasive,
Read More
  • PR NEWSWIRE

Neuralace Medical Announces Upcoming Abstract Presentation at the 26th Annual North American Neuromodulation Society meeting (NANS) showcasing its FDA-cleared, Non-Invasive Axon Therapy® for Chronic Pain

Dr. Marshall Bedder from the Department of Veterans
Dr. Marshall Bedder from the Department of Veterans Affairs, Augusta, Georgia VA Pain Medicine Service will be presenting his observational study, 'Transcutaneous Magnetic Stimulation for Chronic Neuropathic Pain', highlighting the impact of Axon Therapy on a
Read More
  • PR NEWSWIRE

NEURALACE MEDICAL ANNOUNCES THE AMERICAN MEDICAL ASSOCIATION ISSUES UNIQUE CATEGORY III CPT® CODE FOR TRANSCUTANEOUS MAGNETIC NERVE STIMULATION

THE CPT CODE ESTABLISHES A STANDARD REIMBURSEMENT PATHWAY
THE CPT CODE ESTABLISHES A STANDARD REIMBURSEMENT PATHWAY FOR THIS NEW PROCEDURE WHICH IS PERFORMED WITH THE COMPANY'S AXON® THERAPY SYSTEM
Read More
Contact us for Press & Media Inquiries
CONTACT US

Keith Warner

Chief Executive Officer

Proactive and engaging leader with expertise in advanced strategy development and implementation driving outstanding corporate growth. Over 25 years of senior level business acumen gained through key executive positions with leading large cap to venture stage startups within the life sciences and medical technology sectors. Experience in organization-building geared to achieve near and long term milestones both in domestic and international settings. Ability to deliver significant transformation and growth in financial performance, product development, investor fundraising, capital restructuring, P&L management, and strategic planning.